NFATC1 and early-onset autosomal dominant Alzheimer disease: In Alzheimer’s disease (AD) patients [10], circPSEN1 is significantly up-regulated, promoting amyloid-β (Aβ) production by inhibiting miR-137 expression and activating the nuclear factor of activated T cells 1 (NFATC1) and epidermal growth factor receptor (EGFR) pathways [11].